U.S. markets closed

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2832-0.0067 (-2.31%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2899
Open0.2677
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2677 - 0.2926
52 Week Range0.0940 - 0.4400
Volume511,014
Avg. Volume900,574
Market Cap112.648M
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.0940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Next Super Stocks on the Move: Tetra Bio-Pharma, Red Light Holland, FansUnite, and Skylight Health

    Trending Sectors in Focus: Sports Betting, I-Gaming, Psychedelics, Healthcare, and Biopharma InnovationNEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestrea

  • Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
    ACCESSWIRE

    Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 * The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenueOTTAWA, ON / ACCESSWIRE / June 2, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today tha

  • Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting
    CNW Group

    Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that all matters presented for approval at the Company's annual general and special meeting (the "Meeting") of shareholders of the Company held earlier today via live audio webcast online were approved.